# Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.

> **NCT05937906** · PHASE1,PHASE2 · RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 24 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Phase I - Mirdametinib - Level 1
- **DRUG:** Phase II - Mirdametinib
- **DRUG:** Phase I - Mirdametinib - Level 2
- **DRUG:** Phase I - Mirdametinib - Level 3
- **DRUG:** Phase I - Mirdametinib - Level 4

## Key facts

- **NCT ID:** NCT05937906
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2028-05-25
- **Final completion:** 2028-05-25
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05937906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05937906, "Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05937906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*